ABSTRACT
Preclinical studies and small clinical trials suggest that glucagon-like peptide 1 (GLP1) may have a positive effect on ventricular function. Liraglutide is a GLP1-analogue used in the treatment of type 2 diabetes. LIPER2 is a phase IV, randomised, double-blind, placebo-controlled, parallel-design trial, assessing the effect of 6 months' liraglutide 1.8 mg/d on measures of cardiac function and physical performance in patients with type 2 diabetes. A total of 30 patients with type 2 diabetes will be included, if their HbA1c is between 7 and 10% while on oral agents (including metformin if tolerated and not contraindicated), a maximum of 2 intermediate or long-acting insulin injections per day or a combination of both. After their baseline examinations, patients are randomised to receive a daily subcutaneous liraglutide or placebo injection (titrated to 1.8 mg/d if tolerated) for 6 months. The primary end-point is the maximal oxygen consumption during cycle ergometry at the end of the study period. Other end-points include distance covered during a 6-min walk test, left ventricular ejection fraction and other measures of ventricular systolic and diastolic functions assessed by echocardiography, heart rate, blood pressure, pro-brain natriuretic peptide, C-reactive protein, HbA1c, lipids, apolipoprotein B, body weight and waist girth. Safety end-points include adverse event reporting, blood count, kidney and liver function, amylase, lipase, electrolytes, calcitonin, CA19.9 and pregnancy test for fertile women. At the time of this report, recruitment is still ongoing. Results are expected to be reported in December 2016.
ABSTRACT
No disponible
Subject(s)
Humans , Metabolic Syndrome/epidemiology , Age Factors , Cross-Sectional Studies , Geographical Localization of RiskABSTRACT
La medicina presenta cambios clínicos, terapéuticos, y tecnológicos, coincidiendo con variaciones demográficas culturales y epidemiológicas. Este conjunto de factores y la rapidez con la que se suceden las innovaciones en todos los campos, obliga a replantearse la formación de los médicos, no sólo durante su periodo inicial universitario, sino también a lo largo de toda su vida profesional. Los tribunales de selección de los profesionales que llevarán el peso de la formación universitaria, deben de atender a todas estas dimensiones para asegurar que los futuros profesores transmitan estos valores a los estudiantes. A su vez, los candidatos deben de conocer aquellos puntos sobre los que construir su currículum (AU)
Medicine is undergoing clinical, therapeutic and technological changes, and this is coinciding with demographic, cultural and epidemiological variations. These factors, and the speed with which innovations occur in all fields, requires a rethink of doctors' training, not only during their initial university studies but also throughout their professional life. Those responsible for appointing medical school lecturers must take into account all these aspects in order to ensure that the teaching staff of the future will transmit these values to students. In turn, candidates must be aware of the key aspects around which they should develop their curriculu (AU)
